This review aims to summarize the current evidence on the treatment of viral hepatitis, focusing on its clinical management. Also, future treatment options and areas of potential research interest are detailed. PubMed and Scopus databases were searched for primary studies published within the last ten years. Keywords included hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus, hepatitis D virus (HDV), hepatitis E virus, and treatment. Outcomes reported in the studies were summarized, tabulated, and synthesized. Significant advances in viral hepatitis treatment were accomplished, such as the advent of curative therapies for hepatitis C and the development and improvement of hepatitis A, hepatitis B, and hepatitis E vaccination. Targeted antiviral medications against HBV (immunomodulatory therapies and gene silencing technologies) are potential ways to eradicate the virus, however there are currently no pharmaceuticals that cure hepatitis B beyond viral suppression. In the end, widespread test-and-treat initiatives with high screening rates and high immunization rates may eradicate viral hepatitis and lessen its impact on healthcare systems. Although more research is needed, the discovery of a cure for hepatitis C has rekindled interest in curing hepatitis B. Clinical research is now being conducted on novel therapy approaches that target the HDV life cycle. It is possible to avoid viral hepatitis A, B, and E infections with effective vaccinations. Over 90% of people with chronic hepatitis C can be cured with new oral, well-tolerated therapy regimens. People with chronic hepatitis B virus infection can also receive effective therapy; however, for the majority of patients, this treatment must be long-term, and more recent advancements hope to provide a "functional cure" for hepatitis B. The latest recent developments in viral hepatitis diagnosis and therapy are covered in this review article.

Hepatitis A virus, hepatitis B virus, hepatitis C virus

Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol. 2021 Jun 21;27(23):3249-3261. doi: 10.3748/wjg.v27.i23.3249.

Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov O. A, Khamroev T. T. Evaluation of Antifibrotic Activity of a Combination of a New Phytocomposition and Proanthocyanidins in Rats.Biomed Pharmacol J 2024;17(4).

Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160274. doi: 10.1098/rstb.2016.0274.

Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol. 2019;25:2591–2602. doi: 10.3748/wjg.v25.i21.2591.

World Health Organization. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015. In: Global hepatitis report 2017 [cited 16 March 2021]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ [Ref list]

Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761

World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. WHO 2016 [cited 16 March 2021]. Available from: WHO_HIV_2016.04_eng.pdf.

Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.

Săndulescu O, Matičič M, Garcia F, Blomé MA, Mondelli MU, Irving W, Zidovec-Lepej S, Widell A, Şahin GÖ. Evolving Insights into Viral Hepatitis: Advances, Evidence, and Expert Perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH)—Part 2:

Hepatitis B, C, and Delta. Germs. 2025; 15(3):263-273. https://doi.org/10.18683/germs.2025.1473

Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07

Hakansson, A.; Alanko Blome, M.; Isendahl, P.; Landgren, M.; Malmqvist, U.; Troberg, K. Distribution of intranasal naloxone to potential opioid overdose bystanders in Sweden: Effects on overdose mortality in a full regionwide study. BMJ Open. 2024, 14, e074152.

Blome, M.A.; Braback, M.; Alsterberg, S.; Jerkeman, A. Hepatitis C treatment at a Swedish needle exchange program, a successful model of care—The ACTIONNE study. Int. J. Drug Policy. 2021, 96, 103407.

Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670

Conway, A.; Valerio, H.; Alavi, M.; et al. A Testing campaign intervention consisting of peer-facilitated engagement, point-of-care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: The ETHOS Engage Study. Viruses 2022, 14. Not, A.;

Saludes, V.; Galvez, M.; et al. Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program. J. Med. Virol. 2023, 95, e28544.

Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue0 5-02.

Ivanova Reipold, E.; Shilton, S.; Donolato, M.; Fernandez Suarez, M. Molecular point-of-care testing for hepatitis C: Available technologies, pipeline, and promising future directions. J Infect Dis. 2024, 229, S342–S349.

Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ахмедова Д.И., Ҳамроев Т.Т. Сафорофлавонозиднинг сурункали токсик гепатит фонида жигарнинг асосий функцияларига таъсирини ўрганиш. Mutafakkir илмий журнал 2022 й, № 2, 37 – 43.

Thomadakis, C.; Gountas, I.; Duffell, E.; et al. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2024, 36, 100792.

Martinello, M.; Solomon, S.S.; Terrault, N.A.; Dore, G.J. Hepatitis C. Lancet 2023, 402, 1085–1096.

Aripov A. N., Aripov O. A., Akhunjanova L. L., Nabiev A. O., Karimov Sh. B., Muhammadjonov B. B., & Khamroev T. T. (2022). Achievements and prospects in the diagnosis and treatment of hepatitis, current problems of viral etiology of hepatitis in children. American Journal of Interdisciplinary Research and Development, 7, 117–124. Retrieved from https://ajird.journalspark.org/index.php/ajird/article/view/212

Yuen, M.F.; Lim, S.G.; Plesniak, R.; et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N. Engl. J. Med. 2022, 387, 1957–1968.

Besombes, C.; Njouom, R.; Paireau, J.; et al. The epidemiology of hepatitis delta virus infection in Cameroon. Gut 2020, 69, 1294–1300.

Fayzullaeva, Z., Agzamova , A. ., & Bekjanova , J. (2025). Viral hepatitis, the relevance of improving their diagnostic methods and promising preventive measures. Евразийский журнал медицинских и естественных наук, 5(5), 44–52. извлечено от https://in-academy.uz/index.php/EJMNS/article/view/51138

Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives. World J Gastroenterol. 2021 Jul 14;27(26):4018-4044. doi: 10.3748/wjg.v27.i26.4018.

A.N. Aripov, O.A. Aripov, L.L. Akhunjanova, A.O’. Nabiev, B.B. Muhammadjonov, Karimov Sh.B., & Khamroev T.T. (2022). Problems and relevance of early diagnosis and treatment of severe hereditary and acquired diseases in children. Frontline Medical Sciences and Pharmaceutical Journal, 2(07), 6–15. https://doi.org/10.37547/medical-fmspj-02-07-02